Coronary Stenosis Clinical Trial
— HOWTO-BRSOfficial title:
HOW To Optimally Implant BioResorbable Scaffold - Intravascular Imaging Versus Quantitative Coronary Angiography Guidance
Verified date | July 2022 |
Source | Asan Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this trial is to compare clinical outcomes between imaging-guided and QCA-guided strategy in patients with native coronary artery disease undergoing BRS implantation.
Status | Terminated |
Enrollment | 84 |
Est. completion date | July 7, 2022 |
Est. primary completion date | February 20, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: - Men or women at least 19 years of age - Typical chest pain or objective evidence of myocardial ischemia suitable for elective percutaneous coronary intervention - Native coronary artery lesions with lesion length 50mm and less and reference vessel diameter of 2.5 ~ 3.75mm by quantitative coronary angiography assessment - The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site. Exclusion Criteria: - Angiographic exclusion criteria: any of the followings 1. Small vessel: mean reference size < 2.5 mm by quantitative coronary angiography 2. True bifurcation lesion with a large side branch (reference vessel diameter > 2.3mm) requiring a complex two-stent approach 3. Left main lesions 4. Ostial lesions within 3mm of the origin: right coronary artery, left anterior descending, or left circumflex artery 5. Impaired delivery of the Absorb bio- resorbable vascular scaffold is expected: - Extreme angulation (=90°) proximal to or within the target lesion. - Excessive tortuosity (=two 45° angles) proximal to or within the target lesion. - Moderate or heavy calcification proximal to or within the target lesion. 6. In-stent restenotic lesions - ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (with 12- 24 hour after symptoms onset) - Prior percutaneous coronary intervention within the target vessel during the last 12 months. - Prior percutaneous coronary intervention within the non-target vessel or any peripheral intervention is acceptable if performed anytime >30 days before the index procedure, or between 24 hours and 30 days before the index procedure if successful and uncomplicated. - Left ventricular ejection fraction (LVEF) < 30% - Hypersensitivity or contraindication to device material and its degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated. - Persistent thrombocytopenia (platelet count <100,000/µl) - Any history of hemorrhagic stroke or intracranial hemorrhage, transient ischemic attack or ischemic stroke within the past 6 months - A known intolerance to a study drug (aspirin, clopidogrel or ticagrelor) - Patients requiring long-term oral anticoagulants or cilostazol - Any surgery requiring general anesthesia or discontinuation of aspirin and/or an Adenosine diphosphate(ADP) antagonist is planned within 12 months after the procedure. - A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer. - Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study. - Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (alanine transaminase (ALT) or aspartate transaminase (AST) > 3 times upper limit of normal). - Life expectancy < 5 years for any non-cardiac or cardiac causes - Unwillingness or inability to comply with the procedures described in this protocol. - Patient's pregnant or breast-feeding or child-bearing potential. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Asan Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Seung-Jung Park | CardioVascular Research Foundation, Korea |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Target lesion failure | the cumulative incidence of cardiac death, target vessel myocardial infarction or ischemia-driven target lesion revascularization at 12 months after the index procedure. | 1 year | |
Secondary | Device success | Successful delivery and deployment of the study scaffold at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold residual stenosis of less than 30% by quantitative coronary angiography (QCA). | 1 hour after an index procedure | |
Secondary | Procedural success | Achievement of final in-scaffold residual stenosis of less than 30% by quantitative coronary angiography with successful delivery and deployment of at least one study scaffold at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel myocardial infarction or repeat target lesion revascularization during the hospital stay. | 24 hours after an index procedure | |
Secondary | Death | cardiac, vascular, non-cardiovascular | 1 year, and 5 years | |
Secondary | Myocardial infarction | 1 year, and 5 years | ||
Secondary | Scaffold thrombosis | 1 year, and 5 years | ||
Secondary | Stroke | 1 year, and 5 years | ||
Secondary | Target lesion revascularization | 1 year, and 5 years | ||
Secondary | Any revascularization | 1 year, and 5 years | ||
Secondary | Target lesion failure (TLR) | cardiac death, target vessel myocardial infarction or ischemia-driven target lesion revascularization | 1 year, and 5 years | |
Secondary | A composite event | a composite event of cardiac death, target vessel myocardial infarction, stroke, or clinically significant bleeding(clinically significant bleeding by Bleeding Academic Research Consortium (BARC) type 2,3,4,5) | 1 year, and 5 years | |
Secondary | In-scaffold restenosis on coronary CT angiography | 1 year, and 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT03427996 -
Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice
|
||
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Completed |
NCT01184183 -
Trial Comparison of Accuseal and Bovine Pericardial Patch During Endarterectomy
|
||
Completed |
NCT00697372 -
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis
|
Phase 4 | |
Completed |
NCT05509296 -
Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease
|
N/A | |
Recruiting |
NCT03054324 -
Validation of a Predictive Model of Coronary Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis
|
||
Enrolling by invitation |
NCT06194526 -
Whole Blood Transcriptomic Signal According to Coronary Atherosclerotic Plaque Burden Assessed by CT Angiography
|
||
Not yet recruiting |
NCT06039748 -
Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
|
||
Not yet recruiting |
NCT05753085 -
Multimodality Optical and Ultrasound Intravascular Imaging for Stent Optimization and Atheroma Assessment
|
N/A | |
Not yet recruiting |
NCT05471687 -
Evaluation of the Functional Impact of Coronary Stenoses in Diabetics by Spectral CT
|
N/A | |
Not yet recruiting |
NCT04569669 -
The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis
|
N/A | |
Active, not recruiting |
NCT02508714 -
Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents
|
N/A | |
Completed |
NCT03301246 -
Artimes Pro Low Profile Dilatation Catheters for Pre-Dilatation in Patients With Symptomatic Ischemic Heart Disease
|
N/A | |
Completed |
NCT03606330 -
Systemic, Pancoronary and Local Coronary Vulnerability
|
||
Completed |
NCT02870140 -
Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent
|
N/A | |
Not yet recruiting |
NCT06071702 -
IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
|
N/A | |
Completed |
NCT02275143 -
Computed Tomography (CT) Coronary Angiogram Evaluation in Cancer Patients Having CT Thorax, Abdomen and Pelvis
|
N/A | |
Active, not recruiting |
NCT01794065 -
The Promus Element Rewards Study
|
N/A | |
Completed |
NCT02120859 -
Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty
|
Phase 4 |